Epstein Matthew S, Wicknick Fredrick W, Epstein Joel B, Berenson James R, Gorsky Meir
University of Washington, Seattle, WA, USA.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Nov;110(5):593-6. doi: 10.1016/j.tripleo.2010.05.067.
Studies of the use of pentoxifylline and α-tocopherol in osteoradionecrosis of the jaw have suggested their efficacy in this condition. We report an initial case series of pentoxifylline and α-tocopherol for patients with bisphosphonate-associated osteonecrosis (BON).
Six cases referred for management of BON were provided pentoxifylline and α-tocopherol in addition to antimicrobial therapy, and followed for a mean of 10 months.
A 74% decrease in area of bony exposure and symptom control was achieved in these cases.
Pentoxifylline with α-tocopherol may represent a strategy for management of BON. Controlled trials in cases of BON appear warranted.
关于己酮可可碱和α-生育酚用于颌骨放射性骨坏死的研究表明它们对此病症有效。我们报告了己酮可可碱和α-生育酚用于双膦酸盐相关骨坏死（BON）患者的首个病例系列。
6例因BON前来治疗的患者除接受抗菌治疗外，还给予己酮可可碱和α-生育酚，并进行了平均10个月的随访。
这些病例实现了骨暴露面积减少74%并控制了症状。
己酮可可碱与α-生育酚可能是一种治疗BON的策略。对BON病例进行对照试验似乎很有必要。
